Document › Details
Lead Discovery Center GmbH. (1/20/11). "Press Release: Lead Discovery Center and Merck KGaA Enter Collaboration for the Discovery of Anti-cancer Compounds. Research Collaboration May Realize the Potential of Kinase Inhibitors as a Means for Cancer Treatm
|Organisation||Lead Discovery Center GmbH (LDC)|
|Group||Max Planck Society for the Advancement of Science|
|Organisation 2||Merck KGaA|
|Group||Merck (DE) (Group)|
|Product 2||drug discovery services|
|Person||Kirschbaum, Bernhard (Merck Serono 200809 Executive VP Research)|
|Person 2||Klebl, Bert (Lead Discovery Center 200806– CEO)|
The Lead Discovery Center GmbH (LDC), a small molecule drug discovery spin-off of Max Planck Innovation GmbH, announced today that it has signed a cooperation agreement with Merck KGaA for the discovery of kinase inhibitors as potential cancer treatments.
The collaboration is supported by the German Ministry of Education and Research (BMBF) under the BioPharma initiative to strengthen the pharmaceutical value chain in Germany.
Using an innovative kinase technology platform originating from the Chemical Genomics Centre of the Max Planck Society (CGC, Dortmund), Merck Serono, a division of Merck KGaA, and the LDC aim to identify inhibitory compounds against at least one undisclosed kinase target and advance them through the drug discovery process up to pharmaceutical lead compounds.
Kinases are key components of biochemical signalling pathways that control cellular growth, metabolism and differentiation. They have therefore become prime targets for drug discovery and development in many diseases, especially in oncology. "Our proprietary technology allows for the identification of innovative allosteric kinase inhibitors that hold strong potential for improved potency and selectivity," says Prof. Dr. Daniel Rauh, group leader at the CGC. "We are excited about the alliance between the LDC and Merck Serono as it provides us with the unique chance to translate our approach into application."
Under the terms of the agreement, the LDC and Merck Serono will work closely together, with each partner contributing its particular expertise and infrastructure as well as their own resources in the fields of assay development, screening, medicinal chemistry and pharmacology.
"We are delighted about this agreement with the LDC and believe that this collaboration has a great potential to provide the basis for the development of further treatment options in oncology," said Dr. Bernhard Kirschbaum, Executive Vice President, Research and Development, at Merck Serono.
"Merck Serono is a recognized leader in drug discovery and development and we are extremely pleased to team up with them," Dr. Bert Klebl, Managing Director of the LDC, adds. "The alliance is a major milestone for the LDC and could well become a role model for highly efficient and professional collaboration between academia and industry. It verifies LDC's positioning as a translational research center with the aim of leveraging excellent academic research for industrial application and the development of medicines."
Contact for the Lead Discovery Center
Thomas Hegendörfer, Head of Business Development
Tel: +49 231 97 42-7000, Email: firstname.lastname@example.org
Emil-Figge-Straße 76a, 44227 Dortmund, Germany
Contact for the Chemical Genomics Center
Prof. Dr. Daniel Rauh
Tel: +49 231 9742 6480, Email: email@example.com
Otto-Hahn-Str. 15, 44227 Dortmund, Germany
Notes to editors
About the LDC
The Lead Discovery Center GmbH (LDC, www.lead-discovery.de) was jointly developed by Max Planck Innovation and the Max Planck Society as a novel approach to advance findings from excellent basic research into the development of medicines.
With a world-class team of drug discovery experts and seasoned managers, the LDC offers the full scope of drug discovery services - from target to lead - according to the highest industry standards. As an independent enterprise with an entrepreneurial outlook, it is positioned as a translational research center specialized in small molecule drug discovery. LDC collaborates with research institutions and universities as well as with industry. The aim is to transform promising and early-stage projects into pharmaceutical leads that reach initial proof-of-concept in animals and that meet the increasing need for novel therapeutic agents.
The LDC forms the core of Max Planck Innovation's Drug Discovery & Development Center (DDC) that won the "BioPharma strategy competition for medicine of the future", a support program of the German Ministry of Education and Research (BMBF).
About the CGC
The Chemical Genomics Centre is an initiative of the Max Planck Society in cooperation with four companies. It stands for high quality research and strong collaborations between industry and Max Planck research. Key to the research strategy of the CGC is that chemical and biological expertise are being combined and interconnected. Within the CGC small molecules are developed as modulating ligands for proteins enabling cell biological studies of biological systems and the understanding of the function of gene products.
About the BioPharma Initiative
The nationwide "BioPharma strategy competition for medicine of the future" is the key element of The Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung - BMBF) "Pharmaceuticals Initiative for Germany". The "BioPharma" strategy competition aims to promote innovative partnerships between academic institutions, biotechnology and pharmaceutical companies in order to strengthen the pharmaceutical value chain in Germany.
Record changed: 2014-04-24
More documents for Max Planck Society for the Advancement of Science
-  4SC AG. (7/20/16). "Press Release: 4SC Forms International Scientific Expert Panel". Planegg-Martinsried....
-  Bruker Corporation. (6/6/16). "Press Release: Bruker Shows Innovative rapifleX MALDI-TOF/TOF at ASMS 2016". San Antonio, TX....
-  Lead Discovery Center GmbH. (5/11/16). "Press Release: LDC and Boehringer Ingelheim Join Forces to Discover a Novel Approach for the Treatment of Schizophrenia". Dortmund....
-  Lipotype GmbH. (5/10/16). "Press Release: Join the lipid revolution! Lipidomics for Everybody". Dresden....
-  Lead Discovery Center GmbH. (1/21/16). "Press Release: LDC Enters New Industry Partnership for the Discovery of Novel Medicines. LDC and Roche Will Jointly Advance Innovative Drug Discovery Projects". Dortmund....
-  Bruker Corporation. (12/7/15). "Press Release: Bruker Introduces MetaboScape at MetaboMeeting 2015. Novel MetaboScape Software Links Experimental Data to Biology by Pathway Mapping". Cambridge....
-  Bruker Corporation. (12/5/15). "Press Release: Bruker AXS Announces Next-Generation Platform for X-ray Crystallography". Kolkata....
-  Lead Discovery Center GmbH. (9/29/15). "Press Release: LDC and Infinity Pharmaceuticals to Cooperate on the Identification of Novel Drug Discovery and Development Opportunities in Oncology". Dortmund....
-  Novasep S.A.. (9/29/15). "Press Release: Novasep Appoints World-class Scientists to Strengthen Its Advisory Board". Pompey....
-  Max Planck Society. (7/23/15). "Press Release: Emmanuelle Charpentier to Become a Director at the Max Planck Institute for Infection Biology in Berlin"....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)